Sugi Predict

Sugi Predict / Compounds / SCHEMBL2110103

SCHEMBL2110103

SCHEMBL2110103

CC(C)(C)OC(=O)N1CCC(O)(C#C[Si](C)(C)C)CC1

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ RECQL P46063 1/20 0.40
▸ HPGD P15428 1/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ GPR119 Q8TDV5 2/20 0.37
▸ EPHX1 P07099 1/20 0.37
▸ HDAC1 Q13547 1/20 0.36
▸ HDAC8 Q9BY41 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36
▸ SCD5 Q86SK9 1/20 0.36
▸ GRM5 P41594 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Carbon Monoxide SCHEMBL8111273 0.96 USP2 (0.44) USP2SMN1; SMN2RECQLHPGDEPHX2
SCHEMBL15557838 0.92 USP2 (0.42) USP2SMN1; SMN2RECQLHPGDEPHX2
SCHEMBL17602919 0.85 USP2 (0.42) USP2SMN1; SMN2RECQLHPGDEPHX2
SCHEMBL27147762 0.85 USP2 (0.41) USP2SMN1; SMN2RECQLHPGDEPHX2
SCHEMBL31219741 0.83 USP2 (0.40) USP2SMN1; SMN2RECQLHPGDEPHX1
SCHEMBL2892960 0.83 USP2 (0.47) USP2SMN1; SMN2RECQLHPGDEPHX2
SCHEMBL18587326 0.82 USP2 (0.46) USP2SMN1; SMN2RECQLHPGDEPHX2
SCHEMBL25034617 0.81 USP2 (0.45) USP2SMN1; SMN2RECQLHPGDEPHX2
SCHEMBL4692388 0.80 USP2 (0.42) USP2SMN1; SMN2RECQLHPGDGPR119
SCHEMBL20001490 0.79 USP2 (0.44) USP2SMN1; SMN2RECQLHPGDEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3233077-B1 DOPAMINE D2 RECEPTOR LIGANDS BROAD INST INC (US) 2026-05-06 — — EP disclosed
US-12428373-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2025-09-30 — — US disclosed
WO-2025149628-A1 PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE ASTRAZENECA AB (SE) 2025-07-17 — — WO disclosed
CN-113620944-B Novel RET inhibitors, pharmaceutical compositions thereof and uses thereof 广东东阳光药业股份有限公司 2024-10-15 — — CN disclosed
CN-113620945-B RET inhibitor, pharmaceutical composition thereof and application of RET inhibitor in medicines 广东东阳光药业股份有限公司 2024-08-23 — — CN disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS THE BROAD INSTITUTE, INC. (US) 2023-05-11 — — US disclosed
EP-3250571-B1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH INC (US) 2022-11-30 — — EP disclosed
US-11498896-B2 Dopamine D2 receptor ligands THE BROAD INSTITUTE, INC. (US) 2022-11-15 — — US disclosed
EP-1709044-B1 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS MORPHOCHEM AG KOMB CHEMIE (DE) 2008-07-16 — — EP disclosed
US-20080027040-A1 Oxazolidinone-Quinolone Hybrid Antibiotics MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE (DE) 2008-01-31 — — US disclosed
US-20070191389-A1 Biaryl derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-08-16 — — US disclosed
US-20070161627-A1 Antibacterial agents GLAXO GROUP LIMITED (GB) 2007-07-12 — — US disclosed
US-20070161627-A1 Antibacterial agents GLAXO GROUP LIMITED (GB) 2007-07-12 — — US disclosed
EP-1784410-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2007-05-16 — — EP disclosed
EP-1709044-A2 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) 2006-10-11 — — EP disclosed
WO-2006020561-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2006-02-23 — — WO disclosed
WO-2005058888-A2 OXAZOLIDINONE-QUINOLONE HYBRID ANTIBIOTICS Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2005-06-30 — — WO disclosed
US-6048878-A Substituted piperidine derivatives as selective agonists of 5-HT receptors MERCK SHARP & DOHME LTD. (GB) 2000-04-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11498896-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 USP2 1115/4885SMN1; SMN2 1443/4885RECQL 4660/4885
US-20230143552-A1 DOPAMINE D2 RECEPTOR LIGANDS DRD2, SLC6A3, NTSR2 USP2 1115/4885SMN1; SMN2 1443/4885RECQL 4660/4885
US-20070161627-A1 Antibacterial agents NQO2, NQO1, NDUFV2 USP2 3056/4885SMN1; SMN2 2534/4885RECQL 80/4885
US-12428373-B2 Dopamine D2 receptor ligands DRD2, SLC6A3, NTSR2 USP2 1115/4885SMN1; SMN2 1443/4885RECQL 4660/4885
US-20070191389-A1 Biaryl derivatives GRM1, GRIN1, GRIN2B USP2 4455/4885SMN1; SMN2 281/4885RECQL 2203/4885
US-20080027040-A1 Oxazolidinone-Quinolone Hybrid Antibiotics OXA1L, TOP1, TOP2A USP2 3130/4885SMN1; SMN2 4448/4885RECQL 51/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.